News

Following the expiration of the exclusive supply contract, Span-America will be able to sell its proprietary PressureGuard CFT therapeutic support surfaces to non Hill-Rom customers, and Hill-Rom will

This treatment also results in fewer days spent in hospital to manage adverse events when compared to intravenous therapy. The report is published in Annals of Oncology, which

The updated clinical data from the pivotal international Phase III trial reported median time-to-disease progression (TTP) in patients receiving lenalidomide plus dexamethasone compared to patients receiving dexamethasone plus

The transaction represents Haemonetics’s third blood management-related acquisition in 2007. Chris Lindop, CFO of Haemonetics, said: “The TEG business acquisition is strategic and strengthens our vision of being

Avexa will move forward with two pivotal clinical trials which have been reviewed and will form the basis for future approval. The end point of the trials will

The company will be able to use these newly patented components to manufacture an optimized vaccine against beta-amyloid, the peptide responsible for the onset of Alzheimer’s disease. The

Focalin XR is manufactured by Elan Holdings for Novartis Pharmaceuticals. Barr filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic Focalin XR

The acceptance for review is an indication that the FDA has determined that the filing is sufficient to complete a substantive review of the application, which customarily takes

The decision was based on preliminary safety data, in which a clinical safety finding of QTc prolongation was observed in one patient. The drug, MK-0457, is being investigated